ARA-290 Research

← Back to Research Library
Research Library

At a Glance

  • What it is: A lab-made peptide engineered from a region of erythropoietin (EPO), built to activate a tissue-protective signaling pathway without EPO’s effect on red blood cells.
  • Research areas: sarcoidosis-associated small fiber neuropathy in three placebo-controlled human trials, smaller human trials in type 2 diabetes and diabetic eye disease, plus mechanism work in nerve-injury, inflammation and wound-healing research models.
  • Evidence level: Real human trial data exists, all of it small and short, and most of it in one rare-disease population. ClinicalTrials.gov lists no trial beyond phase 2.
  • The short version: ARA-290 has real, published human trial data behind it, which is genuinely uncommon in this category. That data is narrow: small groups followed for four to twelve weeks, mostly one disease population, and a development program that never reached a phase 3 trial.

On this page: Quick facts · What the human trials found · How it works · Limits · Common questions

ARA-290, also called Cibinetide, is a peptide built from the helix-B surface region of erythropoietin, the part of the molecule tied to tissue protection rather than red blood cell production. Researchers designed it to activate that protective signaling on its own, separate from EPO’s better-known blood effects.

A quick note on framing. Most of the human trials discussed below studied people with sarcoidosis, a rare inflammatory disease, and specifically those with small fiber neuropathy symptoms from it. The others studied people with type 2 diabetes. None of them tested it as a treatment in healthy adults. We cite that literature below as research.

Image coming soon
Available at Etched Research (pre-order)
First lot being sourced now. No independent lab report is on file for this compound. For research use only.

View product →

Quick facts

  • Names: ARA-290, cibinetide (the generic drug name), ARA 290, ARA290, pHBSP, short for pyroglutamate helix B surface peptide (PubChem).
  • What it is: an 11-amino-acid peptide (pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser), formula C51H84N16O21, 1257.3 g/mol (PubChem CID 91810664). It copies the outer face of helix B in EPO and was first described in 2008. In that work, neither it nor helix B raised red blood cell production in cells or in animals (Brines et al., PNAS, 2008).
  • Human trials: five small trials in patients, from 9 to 64 people and four to twelve weeks long, are summarized below. A sixth gave 2 mg to 36 healthy volunteers to study emotional processing, and found no effect on mood (Cerit et al., 2015).
  • Approval: we found no drug approval for cibinetide from the FDA or any other regulator. Its developer, Araim Pharmaceuticals, announced an FDA orphan drug designation for sarcoidosis in July 2016, which marks a drug in development, not an approved one (Araim announcement). ClinicalTrials.gov lists no cibinetide trial beyond phase 2 (ClinicalTrials.gov, searched 24 September 2026).

What the research found, and what it did not

The trials below ran in adults with sarcoidosis-related nerve damage, in adults with type 2 diabetes and in adults with diabetic eye disease. The results are listed as reported, including the ones that missed.

Pilot trial in sarcoidosis-associated neuropathy (Molecular Medicine, 2012). A randomized, double-blind, placebo-controlled study in 22 adults with sarcoidosis and small fiber neuropathy symptoms. Researchers gave ARA-290 by IV, three times a week for four weeks, and measured a standard neuropathy symptom score. The treatment group improved significantly more than placebo. Pain and fatigue scores improved about equally in both groups, and mood did not change. PMID 23168581. https://pubmed.ncbi.nlm.nih.gov/23168581/

Second sarcoidosis trial (Molecular Medicine, 2013). A blinded, placebo-controlled trial in 38 adults with sarcoidosis and small nerve fiber loss, 21 on ARA-290 and 17 on placebo, given daily under the skin for 28 days. Researchers reported improved neuropathy symptoms, a rise in corneal small nerve fiber density and a longer 6-minute walk in the ARA-290 group. PMID 24136731. https://pubmed.ncbi.nlm.nih.gov/24136731/

Type 2 diabetes trial (Molecular Medicine, 2015). A phase 2, placebo-controlled trial in adults with type 2 diabetes and painful neuropathy, given daily under the skin for 28 days and followed for one more month. Researchers reported improved HbA1c, blood lipids and neuropathy symptoms. Corneal nerve fiber density rose only in the subgroup that started lowest. PMID 25387363. https://pubmed.ncbi.nlm.nih.gov/25387363/

Phase 2b trial, the larger follow-up (Investigative Ophthalmology & Visual Science, 2017). A randomized, placebo-controlled trial in 64 people with the same underlying condition. They took placebo or one of three daily doses (1mg, 4mg, or 8mg) for 28 days. Researchers measured corneal nerve fiber area, a structural marker of small nerve fiber loss, using corneal confocal microscopy. Nerve fiber area rose significantly more than placebo at the 4mg dose, an average placebo-corrected gain of 697 square micrometers, but not at 1mg or 8mg. Regrowing nerve fibers in skin samples also rose at 4mg. Pain improved in every group, placebo included. PMID 28475703. https://pubmed.ncbi.nlm.nih.gov/28475703/

Diabetic macular edema trial (Journal of Clinical Medicine, 2020). A phase 2 trial with no placebo group in 9 adults with swelling at the back of the eye from diabetes, 8 of whom finished 12 weeks of daily treatment. There was no average improvement in vision, retinal thickness, retinal sensitivity or tear production. A vision-questionnaire score improved. PMID 32674280. https://pubmed.ncbi.nlm.nih.gov/32674280/

Etched Research’s ARA-290 10mg is sold for laboratory research only, and its page lists the identity data.

How it works

Erythropoietin (EPO) is best known for telling the body to make red blood cells. Separately, it can activate a different signaling pathway tied to tissue protection and repair, through a receptor pairing researchers call the Innate Repair Receptor, built from EPOR and a second receptor called CD131.

ARA-290 is built to activate that second pathway specifically, without triggering the red-blood-cell effect. In research models, that activation has been linked to reduced inflammatory signaling and improved tissue repair measures. Because it targets a specific receptor pairing rather than acting broadly, researchers class it as a selective Innate Repair Receptor agonist.

Two mouse studies looked at that pathway more closely. In mice with chemically induced colitis, cibinetide cut the build-up of inflammatory immune cells and improved weight gain and survival. In immune cells tested in a dish, its anti-inflammatory effect needed CD131 and a signaling enzyme called JAK2, and worked by blocking part of NF-kB, a master switch for inflammation (Nairz et al., Scientific Reports, 2017). In mice with genetic diabetes and slow-healing wounds, daily cibinetide improved skin regrowth over the wound, new blood vessel growth and wound strength (Bitto et al., 2018). Both are mouse studies, and both list Araim staff as authors.

What the research does not establish

The honest limits matter more than the headlines.

  • ARA-290 received an FDA orphan drug designation for sarcoidosis, according to its developer, Araim Pharmaceuticals. That is not an approval. ClinicalTrials.gov lists no trial beyond phase 2, and we found no active development program.
  • The trials were small, 9 to 64 people, and most studied one rare disease population. Researchers have not established these results in healthy adults.
  • The trials tracked structural nerve markers, symptom scores and blood markers over four to twelve weeks. They were not built to show broad nerve-health or recovery outcomes in people without these conditions.
  • Araim staff are authors on four of the five patient trials above, and none has been repeated at a larger size.
  • Mechanism research exists in animal models of inflammation and wound healing, including colitis and diabetic wounds in mice. Those are research-model findings, not human outcomes.
  • This page is a research summary only.

Common questions

Is ARA-290 FDA approved?

No approval was found. The FDA status its developer announced is an orphan drug designation for sarcoidosis in 2016, which is given to drugs still in development (Araim announcement). The largest published trial was a 64-person phase 2b (Culver et al., 2017), and ClinicalTrials.gov lists no later phase (ClinicalTrials.gov).

Is ARA-290 good for neuropathy?

That is what most of the human research tested, and the answer so far is limited. In adults with sarcoidosis-related small fiber neuropathy, a 22-person pilot found a better symptom score than placebo but no difference in pain (Heij et al., 2012). The 64-person phase 2b found a rise in corneal nerve fiber area at one of three doses, and pain improved in the placebo group too (Culver et al., 2017). No trial ran longer than twelve weeks, and none has been repeated at a larger size.

What is the difference between ARA-290 and EPO?

EPO is a full-size hormone that drives red blood cell production. ARA-290 is an 11-amino-acid piece modeled on one surface of EPO. Its designers reported that it kept EPO’s tissue-protective activity in animal models but did not raise red blood cell production in cells or animals (Brines et al., PNAS, 2008). In rats and mice with nerve injury, it had no effect in mice lacking the CD131 receptor, which points to that receptor as its route of action (Swartjes et al., 2011).

What is the innate repair receptor?

It is the name researchers gave to a second form of the EPO receptor. When EPO receptors pair with each other, they signal red blood cell production. When an EPO receptor pairs with CD131, also called the beta-common receptor, the pair is called the innate repair receptor and is linked to tissue protection in research models (Nairz et al., 2017). ARA-290 was designed to act on that second pair only.

What side effects have cibinetide trials recorded?

The trials reported few. The 2012 pilot raised no safety concerns in clinical or lab checks (Heij et al., 2012), the 2015 diabetes trial identified no potential safety issues (Brines et al., 2015), and the 9-person eye trial saw no serious adverse events and no antibodies to the peptide (Lois et al., 2020). These were small, short trials. None of this is a safety conclusion.

Last reviewed 2026-09-24.


For Research Use Only. Not for human consumption. Etched Research supplies compounds for laboratory and research use only. Nothing on this page is medical advice, a health claim, or a recommendation to use.

Scroll to Top